Document Detail

The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model.
MedLine Citation:
PMID:  21340652     Owner:  NLM     Status:  MEDLINE    
We investigated the anti-tumor effect of peritumoral resveratrol in combination with immunotherapy in vivo in neuroblastoma-bearing mice. Subcutaneous NXS2 tumors were induced in A/J mice. On day 10, some mice received 15 mcg of intravenous immunocytokine for 5 days, mice received 20 mg of peritumoral resveratrol twice a week (starting on day 12) for a total of 5 injections, and a separate group received a combination of both regimens. Tumor progression and survival were assessed every 3-4 days. Blood and primary tumor tissue samples were collected on day 20 for Complete Blood Count and CD45 immunohistochemistry and histology, respectively. The primary tumor regressed in all mice receiving peritumoral resveratrol. Most of these mice receiving peritumoral resveratrol alone developed metastatic tumors and recurrence of the primary tumor after cessation of therapy. When resveratrol and immunocytokine regimens were combined, 61% of the mice receiving this combination therapy resolved their primary tumors and survived without developing metastatic tumors, compared to 15 and 13% receiving resveratrol or immunocytokine alone, respectively. None of the therapeutic regimes prevented lymphocyte infiltration or affected the complete blood count. Greater necrosis was observed microscopically in tumors from mice receiving the combination therapy. These results demonstrate that the combination therapy of peritumoral resveratrol plus intravenous immunocytokine provides better anti-tumor effects in this model than either therapy alone.
Brenda L Soto; Jacquelyn A Hank; Tyler J Van De Voort; Lalita Subramanian; Arthur S Polans; Alexander L Rakhmilevich; Richard K Yang; Songwong Seo; KyungMann Kim; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-02-22
Journal Detail:
Title:  Cancer immunology, immunotherapy : CII     Volume:  60     ISSN:  1432-0851     ISO Abbreviation:  Cancer Immunol. Immunother.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-20     Completed Date:  2011-06-17     Revised Date:  2014-11-13    
Medline Journal Info:
Nlm Unique ID:  8605732     Medline TA:  Cancer Immunol Immunother     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  731-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antigens, CD45
Antineoplastic Agents, Phytogenic / blood,  therapeutic use*
Cell Line, Tumor
Combined Modality Therapy
Flow Cytometry
Gangliosides / analysis,  blood
Immunoglobulin G / therapeutic use*
Interleukin-2 / therapeutic use*
Leukocytes / drug effects
Mice, Inbred A
Neoplasm Recurrence, Local
Neuroblastoma / drug therapy*,  immunology,  therapy*
Stilbenes / blood,  therapeutic use*
Tumor Burden / drug effects
Grant Support
CA87025/CA/NCI NIH HHS; F31 GM067386-01/GM/NIGMS NIH HHS; F31 GM067386-02/GM/NIGMS NIH HHS; F31 GM067386-03/GM/NIGMS NIH HHS; F31 GM067386-04/GM/NIGMS NIH HHS; F31 GM067386-04S1/GM/NIGMS NIH HHS; GM67386/GM/NIGMS NIH HHS; P30 CA014520-30/CA/NCI NIH HHS; P30 CA014520-31/CA/NCI NIH HHS; P30 CA014520-31S1/CA/NCI NIH HHS; P30 CA014520-32/CA/NCI NIH HHS; P30 CA014520-32S1/CA/NCI NIH HHS; P30 CA014520-33/CA/NCI NIH HHS; P30 CA014520-33S1/CA/NCI NIH HHS; P30 CA014520-33S2/CA/NCI NIH HHS; P30 CA014520-34/CA/NCI NIH HHS; P30 CA014520-34S1/CA/NCI NIH HHS; P30 CA014520-34S2/CA/NCI NIH HHS; P30 CA014520-35/CA/NCI NIH HHS; P30 CA014520-35S1/CA/NCI NIH HHS; P30 CA014520-36/CA/NCI NIH HHS; P30 CA014520-36S1/CA/NCI NIH HHS; P30 CA014520-36S2/CA/NCI NIH HHS; P30 CA014520-37/CA/NCI NIH HHS; P30 CA014520-37S1/CA/NCI NIH HHS; P30 CA014520-37S2/CA/NCI NIH HHS; P30 CA014520-38/CA/NCI NIH HHS; P30-CA14520/CA/NCI NIH HHS; R01 CA032685/CA/NCI NIH HHS; R01 CA032685-16/CA/NCI NIH HHS; R01 CA032685-17/CA/NCI NIH HHS; R01 CA032685-18/CA/NCI NIH HHS; R01 CA032685-19/CA/NCI NIH HHS; R01 CA032685-20/CA/NCI NIH HHS; R01 CA032685-21/CA/NCI NIH HHS; R01 CA032685-22A1/CA/NCI NIH HHS; R01 CA032685-23/CA/NCI NIH HHS; R01 CA032685-24/CA/NCI NIH HHS; R01 CA032685-25/CA/NCI NIH HHS; R01 CA032685-26A1/CA/NCI NIH HHS; R01 CA032685-27/CA/NCI NIH HHS; R01 CA087025/CA/NCI NIH HHS; R01 CA087025-01A2/CA/NCI NIH HHS; R01 CA087025-02/CA/NCI NIH HHS; R01 CA087025-03/CA/NCI NIH HHS; R01 CA087025-04/CA/NCI NIH HHS; R01 CA087025-05A2/CA/NCI NIH HHS; R01 CA087025-06/CA/NCI NIH HHS; R01 CA087025-07/CA/NCI NIH HHS; R01 CA087025-08/CA/NCI NIH HHS; R01-CA-32685-25/CA/NCI NIH HHS; UL1 RR025011/RR/NCRR NIH HHS; UL1 RR025011-01/RR/NCRR NIH HHS; UL1 RR025011-02/RR/NCRR NIH HHS; UL1 RR025011-03/RR/NCRR NIH HHS; UL1 RR025011-03S1/RR/NCRR NIH HHS; UL1 RR025011-03S2/RR/NCRR NIH HHS; UL1 RR025011-04/RR/NCRR NIH HHS; UL1 RR025011-05/RR/NCRR NIH HHS; UL1RR025011/RR/NCRR NIH HHS
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents, Phytogenic; 0/Gangliosides; 0/Immunoglobulin G; 0/Interleukin-2; 0/Stilbenes; 65988-71-8/ganglioside, GD2; EC, CD45; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gilvimarinus agarilyticus sp. nov., a new agar-degrading bacterium isolated from the seashore of Jej...
Next Document:  Anesthesia for a 228-kg patient (body mass index, 90.6) undergoing laparoscopic sleeve gastrectomy.